PURPOSE: To investigate the effect of intramuscular Botulinum toxin type A (BoNT-A) injection on gait and dynamic foot pressure distribution in children with spastic cerebral palsy (CP) with dynamic equinovarus foot. MATERIALS AND METHODS: Twenty-five legs of 25 children with CP were investigated in this study. BoNT-A was injected into the gastrocnemius (GCM) and tibialis posterior (TP) muscles under the guidance of ultrasonography. The effects of the toxin were clinically assessed using the modified Ashworth scale (MAS) and modified Tardieu scale (MTS), and a computerized gait analysis and dynamic foot pressure measurements using the F-scan system were also performed before injection and at 1 and 4 months after injection. RESULTS: Spastici...
Purpose Botulinum toxin-A (or Botox) is widely used for the management of equinus gait in children w...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
Objective To evaluate the therapeutic effect of botulinum toxin A (BTX-A) injection on spastic gastr...
PURPOSE: The purpose of this paper is to test the hypothesis that combination therapy of serial cast...
The purpose of this pilot study was to evaluate the effect of treatment with botulinum toxin A (BTX-...
PURPOSE: This study used ultrasonography (US) to investigate the architectural changes in gastrocnem...
BackgroundBotulinum toxin type A (BTA) belongs to a therapeutic arsenal of the spastic equinus feet ...
OBJECTIVE: To develop a clinical and instrumental protocol to assess the postural and dynamic effect...
OBJECTIVE: To investigate the benefit of botulinum toxin type A injection into the ankle plantarflex...
The aim of this study was to determine if botulinum toxin type A (BoNT-A) injection into the medial ...
To evaluate whether botulinum toxin type A at standard doses spreads to antagonist leg muscles in dy...
AIM: We compared two botulinum toxin A (BoNT-A) injection frequency regimens, 12-monthly versus 4-mo...
Abstract – We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment ...
The objective of this clinical trial was to compare the efficacy and safety of letibotulinum toxin A...
Purpose Botulinum toxin-A (or Botox) is widely used for the management of equinus gait in children w...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
Objective To evaluate the therapeutic effect of botulinum toxin A (BTX-A) injection on spastic gastr...
PURPOSE: The purpose of this paper is to test the hypothesis that combination therapy of serial cast...
The purpose of this pilot study was to evaluate the effect of treatment with botulinum toxin A (BTX-...
PURPOSE: This study used ultrasonography (US) to investigate the architectural changes in gastrocnem...
BackgroundBotulinum toxin type A (BTA) belongs to a therapeutic arsenal of the spastic equinus feet ...
OBJECTIVE: To develop a clinical and instrumental protocol to assess the postural and dynamic effect...
OBJECTIVE: To investigate the benefit of botulinum toxin type A injection into the ankle plantarflex...
The aim of this study was to determine if botulinum toxin type A (BoNT-A) injection into the medial ...
To evaluate whether botulinum toxin type A at standard doses spreads to antagonist leg muscles in dy...
AIM: We compared two botulinum toxin A (BoNT-A) injection frequency regimens, 12-monthly versus 4-mo...
Abstract – We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment ...
The objective of this clinical trial was to compare the efficacy and safety of letibotulinum toxin A...
Purpose Botulinum toxin-A (or Botox) is widely used for the management of equinus gait in children w...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...